The intersection of HIV treatment and metabolic health presents unique challenges, particularly for the estimated 10-15% of people with HIV who also have type 2 diabetes. Understanding how different antiretroviral therapies affect weight and blood sugar control becomes critical for optimizing long-term health outcomes in this vulnerable population.
A comprehensive analysis of 1,279 HIV-positive adults with diabetes revealed that integrase strand transfer inhibitors (INSTIs) - now considered the preferred first-line HIV treatment - produced an average 2.1 kg greater weight gain compared to older NNRTI-based regimens within twelve months. INSTI users also experienced a modest 0.2 percentage point increase in hemoglobin A1c levels, indicating slightly worse glucose control. The research tracked patients across multiple U.S. and Canadian HIV clinics from 2007 to 2022, with 35% increase in risk for clinically significant weight gain of 5% or more.
This finding adds nuance to the known metabolic effects of modern HIV therapy. While INSTIs have transformed HIV care with superior efficacy and fewer side effects than older drugs, weight gain has emerged as their primary limitation. For people managing both HIV and diabetes, this metabolic burden compounds existing cardiovascular risks. The research suggests clinicians should proactively monitor weight and glucose control when prescribing INSTIs to diabetic patients, potentially implementing earlier lifestyle interventions or diabetes medication adjustments. However, the benefits of viral suppression with INSTIs likely outweigh these metabolic concerns for most patients, making individualized monitoring rather than treatment avoidance the preferred approach.